Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway

Jia-Xing Zhang, Yi Xu, Ying Gao, Cui Chen, Zhou-San Zheng, Miao Yun, Hui-Wen Wang, Dan Xie, and Sheng Ye

Abstract

Background: The development of chemoresistance and metastasis are the leading causes of death for gastric cancer (GC) patients, however, the molecular mechanisms involved remain unclear. Dysregulation of miRNAs is associated with a variety of disease, including GC. Recently, microarray profiling analysis revealed that miR-939 was dysregulated in human GC samples, but the role of miR-939 in GC has not been intensively investigated.

Methods: In the present study, we firstly examined the expression pattern of miR-939 in two independent cohorts of clinical GC samples: one cohort of 112 GC patients with stage I-III disease who underwent surgery followed by adjuvant chemotherapy; and another cohort of 110 GC patients with stage IV disease who received palliative chemotherapy. A series of in vivo and in vitro assays were then performed to investigate the function of miR-939 in GC.

Results: We detected that reduced expression of miR-939 was associated with chemoresistance and increased risk of tumor recurrence in GC patients. Further function study demonstrated that overexpression of miR-939 suppressed GC cell growth, and enhanced 5-fluorouracil-induced chemosensitivity by compromising cellular growth and inducing apoptosis in vitro and in vivo. Moreover, miR-939 repressed the migration and invasion of GC cells in vitro, and diminished the occurrence of lung metastasis in vivo. We further identified solute carrier family 34 member 2 (SLC34A2) as a novel target of miR-939. Mechanistically, we elucidated that miR-939 exerted its function mainly through inhibiting SLC34A2/Raf/MEK/ERK pathway, which is activated in GC. Multivariate analysis identified miR-939, SLC34A2, and their combination as independent indicators for poor prognosis and tumor recurrence in GC patients.

Conclusion: Our data indicate that miR-939 acts as a tumor suppressor miRNA in GC, and miR-939/SLC34A2 axis represents a novel therapeutic strategy for future GC treatment.

Keywords: miR-939, SLC34A2, Gastric cancer, Chemoresistance, Metastasis
Background

Gastric cancer (GC) is one of the most common causes of cancer-related deaths worldwide [1]. At present, surgical resection and palliative chemotherapy are the backbone treatment modalities for early staged and advanced staged GC patients, respectively [2]. Although tremendous progress has been made in therapeutic strategies, the prognosis for GC patients using existing treatments remains unsatisfactory. The development of chemoresistance and metastasis are the leading causes of death for GC patients, however, the molecular mechanisms involved remain unclear [3–5]. Therefore, a better understanding of these molecular events will undoubtedly facilitate our ability to the development of novel therapeutic targets and strategies for GC treatment.

MicroRNAs (miRNAs) are a class of small-regulatory RNA molecules that repress protein translation through binding to the 3′-untranslated region (UTR) of their target mRNA [6]. Aberrant expression of miRNAs has been reported in various types of cancers [7, 8]. In GC, miR-192, miR-215, miR-25 are reported to be upregulated, whereas miR-375, miR-101 are downregulated [9–12]. Nevertheless, the role of miRNAs in the regulation of GC-associated genes, and thus the role of miRNAs in the pathogenesis of GC, remains elusive.

Recently, microarray profiling analysis revealed that a number of miRNAs were dysregulated in human GC samples compared with normal tissues, including miR-939 [13]. However, the clinical significance and biological role of miR-939 in GC is still not known. Therefore, we devised our present study to find out the mechanism of miR-939 action and its potential clinical application in GC. Interestingly, we found that decreased miR-939 expression is closely correlated with poor clinical outcome of GC patients. Our data showed that miR-939 inhibits GC metastasis and enhances the sensitivity of GC cells to 5-fluorouracil (5-Fu) treatment. In addition, we identified that miR-939 exerts its tumor-suppressing role by targeting SLC34A2 via the inhibition of Raf-MEK-ERK signaling pathways.

Methods

Cell lines

Gastric cancer cell lines (AGS, BGC-823, HGC-27, MKN-28, MKN-45, and SGC-7901), and one immortalized human gastric epithelial mucosa cell line (GES-1) were grown in DMEM medium supplemented with 10% fetal bovine serum.

Samples and patients

For the use of clinical materials for research purposes, prior approval was obtained from the Committees for Ethical Review of Research at Sun Yat-Sen University (Guangzhou, China). Formalin-fixed paraffin-embedded (FFPE) tumorous and adjacent non-tumor tissues samples from 112 GC patients, who underwent surgical resection between January 2010 and December 2011, were randomly selected from the archives of the Department of Pathology of Sun Yat-Sen University Cancer Center (Guangzhou, China). All the patients enrolled were diagnosed with stage I-III GC disease during surgery resection, and received postoperative adjuvant 5-Fu-based chemotherapy: SOX regimen (Tegafur plus oxaliplatin), XELOX regimen (capecitabine plus oxaliplatin), Tegafur, or capecitabine. The clinical and pathological characteristics of the patients in this cohort are summarized in Additional file 1: Table 1. The patients were followed every 3 months for the first year and then every 6 months for the next 2 years and finally annually, thereafter. The diagnostic examinations consisted of CT, MRI, abdominal ultrasonography and bone scan when necessary to detect recurrence and/or metastasis. During follow-up period, 71 patients experienced tumor recurrence or metastasis, and 38 deaths due to cancer-related diseases.

In addition, we obtained another independent cohort of 110 patients, who were diagnosed with stage IV GC disease between January 2008 and December 2013. The mean age at diagnosis was 56 years (range, 21–81 years); 81 patients were male. The patients in this cohort were administrated with fluorouracil-based regimen (SOX or XELOX) as first-line palliative chemotherapy. The response of chemotherapy was assessed based on CT examination every 6 weeks during therapy and at the end of treatment according to the following criteria: complete response (CR) as defined by the complete resolution of all assessable lesions; partial response (PR) as defined by a reduction by 50% or more of the sum of the lesions and no progression of assessable lesions; or no change (NC) as indicated by a reduction <50% or increase <25% in tumor size. The CR, PR or NC conditions had to last for at least 4 weeks without appearance of new lesions. Otherwise the response will be counted as progressive disease (PD) as defined by an increase of 25% in tumor size or appearance of new lesions.

The clinical and clinicopathological classification and stage were determined according to the American Joint Committee on Cancer (AJCC) criteria. Patients who had a single primary lesion without neoadjuvant therapy before operation were included in the study. Other criteria for inclusion were as follows: age >18 years; histologically confirmed gastric cancer with at least one measurable lesion as defined by the Response Evaluation Criteria in Solid Tumors; Eastern Cooperative Oncology Group performance status (ECOG PS) of B2, and life expectancy >3 months.

For both XELOX and SOX regimen, oxaliplatin (130 mg/m2) was diluted in 500 mL of 5% dextrose and...
infused intravenously over 2 h on day 1. Oral administration of capecitabine (1000 mg/m2) and Tegafur (body surface area, BSA < 1.25: 40 mg; BSA 1.25–1.5: 50 mg; BSA > 1.5: 60 mg) was followed twice a day from days 2 to 15 in XELOX and SOX regimen, respectively. Treatment was continued until 6–8 cycles of XELOX, SOX, Tegafur, or capecitabine had been completed, disease progression, unacceptable toxicity, patient withdrawal, or physician’s decision.

**RNA isolation and quantitative real-time PCR**

Total RNA was extracted from cultured cells and tissue specimens using TRIzol (Invitrogen, Calsbad, CA). Real-time PCR was carried out with SYBR Green SuperMix (Roche, Basel, Switzerland) using ABI7900HT Fast Real-Time PCR system (Applied Biosystems, Foster City, CA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or U6 was used as an internal control. An optimal cutoff value for “high” or “low” miR-939 expression was identified based on the median value of the cohorts of patients tested. TaqMan probes were used to detect miR-939, SLC34A2, U6, and GAPDH (GeneCopoeia, Guangzhou, China).

**MTT assay**

Cell viability was measured by a 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assay (Sigma, St, Louis, Missouri, USA). Briefly, cells were seeded in 96-well plates and treated with various concentrations of 5-Fu for each well. The absorbance was measured at 570 nm, with 655 nm as the reference wavelength. All experiments were carried out in triplicates.

**Colony formation assay**

Cells were placed in six well plate (500 cells/plate) and cultured for 2 weeks. Colonies were fixed with methanol for 5 min, and stained with 0.1% crystal violet for 30 s.

**Flow cytometric analysis of apoptosis**

Annexin V-APC and propidium iodide (PI) stains were carried out to assess the percentage of cells undergoing apoptosis. The apoptosis assay was conducted using the protocol supplied by the manufacturer (BioVision Inc.). Each sample was then subjected to analyses by flow cytometry (Beckman Coulter, cytomixics FC 500, CA).

**Wound-healing, migration and invasion assays**

For cell wound-healing assay, the movement of cells was measured in a scraped, acellular area made by a 200 ml pipette tube, and the spread of wound closure was observed after 24 h. For migration assay, 40,000 cells were added to the upper chamber in serum free media and migration at 37 °C towards 10% FBS containing growth media was determined either after 24 h. Cells migrated through the membrane were fixed, stained and counted under light microscope. For invasion assays, 1 × 10⁵ cells were seeded into a Matrigel invasion chamber (BD Biosciences, NJ, USA) in a 24-well culture plate. After 24 h, the invasive cells located on the lower side of the chamber were fixed in methanal, stained with crystal violet, and followed by counting under a light microscope.

**Western blot (WB) assay**

Equal amounts of cell protein lysates were resolved by SDS-polyacrylamide gel electrophoresis (PAGE) and electrotransferred on a polyvinylidene difluoride (PVDF) membrane (Pall Corp., Port Washington, NY) according to standard methods. The following primary antibodies were used: anti-SLC34A2 (Abcam, Cambridge, UK); anti-GAPDH, anti-AKT, anti-p-AKT, anti-ERK, anti-p-ERK, anti-c-Raf (Cell Signaling Technology, Beverly, MA).

**Immunohistochemical (IHC) Staining**

In brief, tissue sections were de-waxed and incubated in retrieval buffer solution for antigen recovery. We used the Dako Real Envision Kit (K5007, Dako) to visualize protein expression after staining with primary antibody. Staining intensity was scored manually by two independent experienced pathologists as 0 = no staining, 1 = weak staining, 2 = moderate staining, and 3 = strong staining. Tumor cells in five fields were randomly selected and scored based on the percentage of positively stained cells (0–100%). The final IHC score was calculated by multiplying the intensity score with the percentage of positive cells (range from 0 to 3). An optimal cutoff value was identified based on the median value of the cohorts of patients tested.

**Vector construction and retroviral infection**

The miR-939 expression vector (HmiR0533-MR03), the control vector for miR-939 (CmiR0001-MR03), the coding sequences of SLC34A2 expression vector (EX-A3175-Lv105), and the control vector for SLC34A2 (EX-NEG-Lv105) were purchased from the GeneCopoeia Company (Guangzhou, China). Cells transfected with empty vector were used as controls. The vectors were packaged using the ViraPower Mix (Genecopoeia, Guangzhou, China) in 293FT cells. After culturing for 48 h, the lentiviral particles in the supernatant were harvested and filtered by centrifugation at 500 g for 10 min, and then transfection into the GC cells.

**Mimic, antagonim, plasmids and transient transfection**

miR-939 mimic and antagonim-939 were purchased from GeneCopoeia Company (GuangZhou, China). Oligonucleotide transfection was performed with Lipofectamine...
2000 reagent (Invitrogen, Carlsbad, CA), according to the manufacturer’s instructions.

**Luciferase reporter assay**
The 3’ UTR of SLC34A2 were amplified and cloned downstream to the luciferase gene in a modified pGL3 control vector. The firefly luciferase construct was cotransfected with a control Renilla luciferase vector into GC cells in the presence of miR-939 mimic, antagomir-939, or miR-control. A dual luciferase assay (Promega) was performed 48 h after transfection. The experiments were performed independently in triplicate.

**Animal experiments**
For in vivo metastasis assays, six Four-week-old BALB/c nude mice in each experimental group were injected with SGC-7901/control or SGC-7901/miR-939 cells, respectively. Briefly, $2 \times 10^5$ GC cells in 30 μl of 33% Matrigel (Becton Dickinson, NJ, USA) were injected intravenously through the tail vein. The experiment was terminated 28 days after tumor-cell inoculation, and metastatic nodules in each lung were counted.

For xenograft growth of orthotopic animal model assay, the mice were randomly divided into four groups ($n=6$): SGC-7901/control, SGC-7901/miR-939, SGC-7901/control + 5-Fu, SGC-7901/miR-939 + 5-Fu, and equal amounts of SGC-7901/miR-939 or SGC-7901/control cells ($3 \times 10^6$) were injected subcutaneously into the flank of each mouse. For chemotherapy treatment group: 5-Fu was administered at a dose of 5 mg/kg at 10 am twice a week for 3 week; for control groups, DMSO alone (100% DMSO, 40 μL, intraperitoneal injection every 2 days) were delivered to the mice. Treatment began on day 7, when the tumors were measurable. The tumors were examined twice weekly, length and width measurements were obtained with calipers, and the tumor volumes were calculated. On day 28, the animals were euthanized and the tumors were excised and weighed.

All the procedures were carried out in accordance with the guidelines of the Laboratory Animal Ethics Committee of Sun Yat-Sen University.

**Statistical analysis**
Statistical analysis was performed using a SPSS software package (SPSS Standard version 16.0, SPSS Inc). Receiver operating characteristic (ROC) curve analysis was conducted to evaluate the predictive value of miR-939 expression in predicting GC chemotherapy response. Comparisons between groups for statistical significance were performed with a 2-tailed Student’s $t$ test. Bivariate correlations between study variables were calculated by Pearson’s correlation coefficients. Differences between variables were assessed by the Chi-square test or Fisher’s exact test. For survival analysis, we analyzed all GC patients by Kaplan-Meier analysis. A log rank test was used to compare different survival curves. Multivariate survival analysis was performed on all parameters that were found to be significant in univariate analysis using the Cox regression model. $P$ values <0.05 were considered significant.

**Results**
Expression of miR-939 is downregulated in GC and closely related to clinical outcomes
To explore miR-939 expression in GC, we conducted real-time PCR assay. As shown in Fig. 1a, b, the expression of miR-939 was significantly decreased in human GC cell lines and human primary GC tissues compared with normal gastric epithelial cell lines and nontumor human gastric tissues, respectively ($P<0.05$).

Next, we analyzed miR-939 expression using pretreatment tissue samples from 112 GC patients with stage I–III disease who underwent surgery resection followed by adjuvant chemotherapy. We detected that miR-939 levels were significantly decreased in patients who showed local relapse or distant metastasis in comparison to patients who did not have tumor relapse or metastasis during our follow-up period ($P<0.05$, Fig. 1c).

To further determine the clinical implication of miR-939 expression, we conducted qRT-PCR assay in 110 pretreatment samples from stage IV GC patients who received palliative chemotherapy. Among the enrolled cases, there were 0, 57, 36, and 17 patients satisfied the criteria for complete response (CR), partial response (PR), no change (NC) and progressive disease (PD) at the evaluation time, respectively. We observed that miR-939 showed a negative correlation with chemotherapy response in our enrolled cases, in which low expression of miR-939 was observed more frequently in NC + PD subset (41/56, 73.2%) than in CR + PR set (15/56, 26.8%) ($P<0.001$, Table 1). Moreover, Receiver operating characteristic (ROC) curves analysis demonstrated that a promising predictive value of miR-939 regarding GC chemotherapy response (area under the curve [AUC] =0.777, $P<0.001$, Fig. 1d).

miR-939 inhibits the GC growth in vitro and in vivo
Next, we investigated the effects of miR-939 on GC by overexpressing or inhibiting miR-939 in GC cell lines. MTT and colony formation assays revealed that overexpression of miR-939 significantly increased the growth rate of both GC cell lines; conversely, depletion of miR-939 promoted GC cell proliferation and tumorigenicity in vitro (Fig. 1e, f). Next, we sought to determine whether miR-939 sensitized GC cells to 5-Fu treatment, the common used chemotherapeutic drug in GC patients. As shown in Fig. 2a, b, the combination of 5-Fu
with miR-939 was more efficient in reducing the GC cell viability and the clone formation ability. We further examined whether miR-939 increased the sensitivity of GC cells to 5-Fu by enhancing the rate of apoptosis. The AnnexinV-PI assay showed that miR-939-overexpressing cells displayed increased cellular apoptosis and necrosis in response to 5-Fu treatment at 48 h (Fig. 2c). Moreover, a significant increase in level of cleaved caspase-3 and PARP I in miR-939-overexpressing cells treated with 5-Fu was detected by western blot analysis (Fig. 2d).
Together, these results demonstrate that miR-939 promoted the apoptosis of GC cells.

We also demonstrated miR-939's ability to inhibit the GC growth using GC orthotopic animal model in vivo. As shown in Fig. 2e, we found that overexpression of miR-939 could significantly compromise GC tumor growth in vivo, and moreover, the combination of miR-939 and 5-Fu showed more significant inhibition of tumor growth, compared to either miR-939 or 5-Fu alone. Similarly in Fig. 2f, g, the group receiving combination of miR-939 and 5-Fu had lower average tumor weight and volume, compared with the groups receiving miR-939 or 5-Fu alone. More importantly, the combination of miR-939 and 5-Fu is well tolerated by the test animals in vivo, as indicated by mouse body weight (Fig. 2h). Thus, results suggested that miR-939 could enhance the sensitivity of GC cells to chemotherapies in vivo.

### miR-939 inhibits GC cell metastasis in vitro and in vivo

As lower expression of miR-939 was observed in patients with distant metastasis in GC and distant metastasis often resulted in resistance to the conventional chemotherapy drugs, we sought to determine whether miR-939 has inhibition on GC metastasis. We confirmed that overexpression of miR-939 suppressed cellular migration and invasion, whereas miR-939 inhibition promoted migration and invasion in vitro (Fig. 3a-c). Moreover, we stained the cancer cells that spread into lung of mice. Number and size of the metastatic colonization were dramatically decreased on the lung surface of miR939-transfected cells implanted mice compared to the control mice, and the miR-939 overexpression group exhibited much lower Ki-67 IHC staining of tumor metastases than the control group (Fig. 3d).

### miR-939 enhances GC chemosensitivity and inhibits metastasis by directly targeting SLC34A2

Using miRNA target prediction algorithms, we identified solute carrier family 34 member 2 (SLC34A2) as tentative target of miR-939 (Fig. 4a). The luciferase reporter assay indicated that overexpression of miR-939 significantly repressed the luciferase activity of SLC34A2-3’UTR, while inhibition of miR-939 increased the luciferase activity of SLC34A2-3’UTR. Meanwhile, ectopically expressing miR-939 mutation had no inhibitory effect on the SLC34A2-3’UTR luciferase activity (Fig. 4b). As shown in Fig. 4c, d, the expression levels of SLC34A2 mRNA and protein were significantly decreased following the ectopic expression of miR-939; In contrast, the inhibition of miR-939 led to an increase in the expression of SLC34A2 at both the mRNA and protein level. Consistently, overexpressing miR-939 mutation had no compromising effect on SLC34A2 mRNA and protein expression level (Fig. 4c, d). Moreover, our clinical data show that the expression levels of miR-939 and SLC34A2 were negatively correlated in 112 GC samples (r = -0.623, P < 0.001, Fig. 4e).

To determine whether SLC34A2 directly contribute to miR-939 function, SLC34A2 was overexpressed in miR-939-overexpressing GC cells (Fig. 5a). As expected, restoration of SLC34A2 can block the miR-939-enhanced chemosensitivity and induction of apoptosis by 5-Fu treatment (Fig. 5b-d). Also, exogenously expressed SLC34A2 compromised the inhibition of metastasis by miR-939 on GC cells (Fig. 5e-f). Taken together, these data suggest that SLC34A2 played an important role for the effects of miR-939 on GC cells.

### miR-939 attenuates ERK1/2 phosphorylation and inhibits the Raf-MEK-ERK pathway

Previous studies have documented that PI3K/AKT and MAPK/ERK signaling pathway play crucial roles in development of chemoresistance and metastatic ability in human malignancies [14–16], thus we investigated the roles of miR-939 in the activation of PI3K/AKT and MAPK/ERK pathway. We found that the expression level of P-ERK was significantly decreased in cells with stable overexpression of miR-939 (Fig. 5g, lane 1, 2). This effect was reversed when we restored the SLC34A2 expression (Fig. 5g, lane 3). And pretreatment with ERK inhibitor U0126 could obviously reduce the expression level of P-ERK (Fig. 5g, lane 4). However, the P-AKT and AKT levels were not significantly altered. The observation that miR-939 compromised ERK1/2 activation leads us to further investigate the effect of miR-939 overexpression on RAS-RAF-MEK-ERK pathway. We found obvious inhibition of RAF-MEK-ERK pathway upon miR-939 overexpression, whereas restoration of SLC34A2 attenuated this compromising effect (Fig. 5h).

### Clinical significance and prognostic values of miR-939 and SLC34A2 in GC patients

We evaluated the prognostic significance of miR-939 and SLC34A2 protein expression levels in the GC patients who underwent surgery followed by chemotherapy. GC patients with high levels of miR-939 showed better overall survival

### Table 1 Correlation between the expression of miR-939 and therapy response in GC patients (N = 110)

| Therapy response | All cases | Low expression | High expression | P value |
|------------------|----------|----------------|-----------------|---------|
| CR + PR          | 57       | 15             | 42              | P < 0.001 |
| NC + PD          | 53       | 41             | 12              |         |
OS) rates and lower tumor recurrence rates than those with low miR-939 (Fig. 6a, b); whereas GC patients with high levels of SLC34A2 showed poorer OS rates and higher tumor recurrence rates than those with low SLC34A2 (Fig. 6c, d). According to univariate analysis, miR-939, SLC34A2 level, and TNM stage were significantly

**Fig. 2** miR-939 increases cellular sensitivity to 5-Fu in vitro and in vivo. **a** concentration-dependent growth inhibition in response to 5-Fu in miR-939-overexpressing, miR-939-silenced, and control GC cells. **b** quantification of the colony formation efficiency in miR-939-overexpressing, miR-939-silenced, and control GC cells treated with 5-Fu chemotherapy. **c** miR-939 sensitizes GC cells to 5-Fu-induced apoptosis. miR-939-overexpressing and vector control cells treated with indicated dose of 5-Fu for 24 h. Cell apoptotic death events were monitored by Annexin V/PI staining and flow cytometry assays. **d** after treatment, cleaved caspase 3 and PARP levels were determined by western blot, and GAPDH was used as a normalized control. The quantitative values under the bands were the relative ratios cleaved PARP, cleaved caspase-3 to GAPDH from densitometric analysis. **e** the same amount (3x10^6) of miR-939-overexpressing and control GC cells were injected subcutaneously into the flanks of nude mice. Starting on day 7, the mice were given 5-Fu or DMSO intraperitoneally. **f**, **g** and **h** the tumor volumes (**f**) and mice weight (**h**) were monitored on day 7 and then every 2 days, as indicated, and the xenografts were excised and weighed on day 25 (**g**). *P* < 0.05, **P** < 0.01.
Fig. 3 (See legend on next page.)
associated with OS and time to recurrence (TTR) in patients with GC (Table 2), while multivariate analysis confirmed miR-939, SLC34A2 level, and TNM stage as independent prognostic indicators for both OS and TTR (Table 2).

Next, we divided patients into four groups based on miR-939 and SLC34A2 expression levels. GC patients with high miR-939 and low SLC34A2 had the best OS, lowest TTR, and best prognosis. In contrast, those with low miR-939 and high SLC34A2 had the poorest

Fig. 3 miR-939 inhibits gastric cancer metastasis in vitro and in vivo. a the wound healing rate in miR-939-transfected cells was significantly inhibited, while accelerated in miR-939-silenced cells. b the number of migrated cell was decreased in miR-939-overexpressing, while increased in miR-939-silenced GC cells, as assessed by tranwell migration assay. c the number of invaded cell was decreased in miR-939-overexpressing, while increased in miR-939-silenced GC cells, as assessed by Matrigel invasion assay. d miR-939 inhibits tumor metastasis in vivo. Left panel: hematoxylin and eosin (H&E) staining was performed on serial sections of metastatic tumors (M) and normal (N) lung. Arrows: lesions of lung. The Ki-67 IHC staining was performed on tumor metasteses. Right panel: the number of nodules was qualified on lungs of SCID mice (n = 6 per group) 4 weeks after tail vein injection of SGC-7901-scramble (left bars) and SGC7901-miR-939 cells (right bars)

Fig. 4 SLC34A2 is the direct target of miR-939. a predicted miR-939 target sequence in 3’UTR of SLC34A2 (SLC34A2-3’UTR) and mutant containing three altered nucleotides in the seed sequence of miR-939 (miR-939-mut). b luciferase assay of pGL3-SLC34A2-3’UTR reporters cotransfected with increasing amounts (10, 20, and 50 nM) of miR-939 mimic and mutant oligonucleotides in GC cell lines, or with increasing amounts (20, 50, and 100 nM) of miR-939 inhibitor oligonucleotides in GC cell line. c real-time RT-PCR analysis showed that overexpression of miR-939 significantly suppressed SLC34A2 mRNA expression level of SLC34A2 of GC cells, while inhibition of miR-939 led to a noticeable increase in SLC34A2 mRNA expression level of GC cell. d western blot analysis demonstrated that miR-939 tranfection decreased SLC34A2 protein level of GC cells, while anti-miR-939 dramatically increased SLC34A2 protein in GC cell. e high SLC34A2 IHC staining was observed in one GC sample with low miR-939 expression (upper panel); one GC sample with high miR-939 expression showed weak GNA13 IHC staining (lower panel). f the expression of SLC34A2 was inversely correlated with the expression of miR-939 in 112 GC samples. * P < 0.05, **P < 0.001
Fig. 5 (See legend on next page.)
prognosis with the lowest OS and highest probability of tumor recurrence ($P < 0.001$; Fig. 6e, f). The combination of miR-939 and SLC34A2 was an independent prognostic indicator for OS and TTR ($P < 0.001$, Table 2). This combination gave even better prognostic power than miR-939 or SLC34A2 alone.

**Discussion**

In this study, we found that miR-939 was indeed downregulated in GC tissues. Importantly, we reported, for the first time, that levels of miR-939 were inversely correlated with local relapse, distant metastasis and chemoresistance in GC patients. In addition, a series of in vitro and in vivo experiments demonstrated that miR-939 diminishes GC cell chemoresistance and metastatic ability by targeting SLC34A2 expression, with consequent inhibition of the Raf-MEK-ERK signaling pathway.

Based on the fact that miRNAs are involved in the initiation and progression of a variety of cancer types, the therapeutic potential value of miRNAs in cancer has been identified. A few in vivo and preclinical studies have reported modulating miRNA expression for cancer treatment [17–19]. In general, the therapeutic modulation of miRNAs is achieved by inhibiting oncogenic miRNAs, or by reconstituting tumor suppressor miRNAs [20, 21]. To our knowledge, the relationship between miR-939 expression and clinical implication in human cancers has not been analyzed previously. Here, we reported that miR-939 could repress tumor metastasis and increase the sensitivity of tumor cells to chemotherapeutic agents in GC. Our results indicated, for the first time, that the combination of miR-939 and 5-Fu was more efficient in killing GC cells in vitro and in vivo than using miR-939 or 5-Fu alone. Besides, we provide comprehensive evidence at cellular levels and in the animal models that miR-939 may be beneficial for GC patients with high risks of tumor recurrence and metastasis. Thus, the examination of miR-939 expression could be applied as an effective additional tool to optimize clinical decisions, enabling clinicians to identify those high-risk GC patients with increased risk of tumor recurrence and/or metastasis. Based on these findings, modulating miR-939 expression in GC appears to be an encouraging prototype therapeutic agent for cancer therapy, which might generate suppressing effect on GC chemotherapy resistance and distance metastasis. In general, these data suggested that miR-939 has a pivotal function in GC pathogenesis, with possible use as a biomarker and intervention point for new therapeutic strategies.

Interestingly, little is known about the role of miR-939 in human cancers, miR-939 is among a unique set of downregulated miRNAs in GC. On the other hand, however, Ying reported upregulation of miR-939 in human ovarian cancer, which promoted cancer cell proliferation [22]. By conducting the current study, we provide compelling biologic as well as clinical evidence that miR-939 plays a tumor suppressive role in human GC. These seemingly contradictory findings suggested a dual role of miR-939 as both a tumor-promoting and suppressive miRNA, underscoring the need to define the specific role of a miRNA in a certain type of cancer. As miRNAs can play multiple roles by targeting different genes, it is possible that a single miRNA could function as both a tumor-promoting or -suppressive miRNA in different tumor types depending on the genes and/or pathways they affect [23–25]. Herein, it remains important to thoroughly understand the molecular mechanisms mediating the differential biologic effects and targets of miR-939 in GC and other cancer types. This also underscored the need to define the differential biologic effects and targets of miR-939 in GC and other cancer types.

As described above, miRNAs can play multiple roles by targeting different genes. In this study, we identified SLC34A2 as miR-939 target genes. The SLC34A2 gene, located on chromosome 4p15.2, is a member of the solute carrier gene family, which mediate the transport of inorganic phosphate into epithelial cells via sodium ion co-transport [26, 27]. Recently, function analyses of SLC34A2 in tumorigenesis have yielded contradictory results in different cancer models. Elevated expression of SLC34A2 has been observed in thyroid cancer and breast cancer [28, 29], but a significantly decreased expression has been reported in non-small cell lung carcinomas tissues [29, 30]. However, the expression pattern and biological role of SLC34A2 in GC has never been reported. Our data indicate that the restoration of SLC34A2 blocked the miR-939
overexpression-induced inhibition of cancer growth, cell proliferation, metastasis, and the induction of apoptosis. In addition, our clinical data show that expression of SLC34A2 is inversely correlated with miR-939 expression, and that patients with high expression of SLC34A2 have a decreased survival rate. These data, combined together, implied a potential oncogenic role of SLC34A2 in GC tumor development and progression.

The Ras/MEK/ERK pathway is a central signaling component that plays vital role in the initiation and regulation of various cellular processes, including proliferation, differentiation, apoptosis and migration [31, 32]. In mitogen-stimulated cells, MEK1/2 activation is directly regulated by MAPKs, including Raf-1 kinase, which phosphorylates 2 serine residues (S218, S222) in the activation loop of MEK, and thus in turn activates ERK1/2.
Numerous reports have shown the aberrant activation of Raf/MEK/ERK pathway in variety of human cancers [36, 37]. Recent studies also demonstrated aberrant regulation of this pathway was associated with cancer chemoresistance [14, 15]. In the present study, we observed that miR-939 overexpression in GC cells significantly decreased MEK1/2 phosphorylation and Raf-1 level, while restoration of SLC34A2 rescued these effects. Taken together, these findings demonstrated that SLC34A2 is an integral mediator of miR-939 function in GC cells via MEK-ERK MAPK pathway inhibition, which is known to be dysregulated in many cancers. However, the mechanism by which miR-939-SLC34A2 activates the MAPK signaling pathway is under investigation in our laboratory currently.

### Conclusion

In summary, we provide comprehensive evidence of the inhibitory effect of miR-939 on GC metastasis, and suggest a critical role of miR-939 in enhancing GC cell’s sensitivities to 5-Fu based chemotherapy. Our findings strongly suggest that miR-939 could be used for the development of novel combinatorial therapy strategies aimed at overcoming chemo-resistance and compromising metastasis in GC.

### Table 2 Univariate and multivariate analysis of factors associated with overall survival and time to recurrence in GC patients

| Clinical Variables | Overall Survival HR (95% CI) | P value | Time To Recurrence HR (95% CI) | P value |
|--------------------|-----------------------------|---------|---------------------------------|---------|
| **Univariate analysis** | | | | |
| miR-939 (high versus low) | 0.122 (0.053–0.281) | <0.001 | 0.228 (0.121–0.429) | <0.001 |
| SLC34A2 (high versus low) | 4.555 (2.241–9.260) | <0.001 | 4.179 (2.247–7.769) | <0.001 |
| Gender (female versus male) | 0.559 (0.294–1.060) | 0.075 | 0.791 (0.441–1.420) | 0.433 |
| Age (≥60 versus < 60 years) | 1.188 (0.614–2.297) | 0.609 | 1.063 (0.588–1.921) | 0.833 |
| T status (T4 versus T1 + 2 + 3) | 2.242 (1.182–4.254) | 0.013 | 1.837 (1.042–3.239) | 0.035 |
| N status (N2 + 3 versus N1 + 2) | 6.324 (2.463–16.239) | <0.001 | 4.928 (2.301–10.555) | <0.001 |
| Clinical stage (III versus II) | 14.407 (3.461–59.972) | <0.001 | 9.070 (3.250–25.313) | <0.001 |
| Tumor size (≥5 cm versus < 5 cm) | 2.080 (1.097–3.947) | 0.025 | 2.057 (1.042–3.631) | 0.013 |
| Tumor grade (G3 versus G1 + 2) | 1.371 (0.667–2.828) | 0.389 | 1.354 (0.716–2.560) | 0.351 |

| Combination of miR-939 and SLC34A2 | | | | |
| II versus I | 3.482 (1.778–15.881) | 0.103 | 2.775 (0.921–7.939) | 0.057 |
| III versus I | 6.822 (1.801–25.842) | 0.005 | 2.971 (1.074–8.219) | 0.036 |
| IV versus I | 24.212 (7.049–83.161) | <0.001 | 4.118 (4.688–26.368) | <0.001 |

| **Multivariate analysis a** | | | | |
| miR-939 (high versus low) | 0.167 (0.070–0.398) | <0.001 | 0.328 (0.168–0.640) | 0.001 |
| SLC34A2 (high versus low) | 2.287 (1.050–4.981) | 0.037 | 2.517 (1.276–4.965) | 0.008 |
| T status (T4 versus T1 + 2 + 3) | 1.642 (0.833–3.233) | 0.152 | 1.403 (0.776–2.533) | 0.262 |
| N status (N2 + 3 versus N1 + 2) | 3.812 (1.426–10.188) | 0.008 | 3.143 (1.418–6.966) | 0.005 |
| Tumor size (≥5 cm versus < 5 cm) | 1.784 (0.929–3.425) | 0.082 | 1.754 (0.982–3.133) | 0.058 |

| **Multivariate analysis b** | | | | |
| II versus I | 3.320 (0.734–15.015) | 0.119 | 2.865 (0.980–8.376) | 0.055 |
| III versus I | 7.988 (2.077–30.727) | 0.003 | 3.444 (1.224–9.689) | 0.019 |
| IV versus I | 15.959 (4.498–56.619) | <0.001 | 7.970 (2.499–19.546) | <0.001 |
| T status (T4 versus T1 + 2 + 3) | 1.697 (0.852–3.382) | 0.133 | 1.423 (0.782–2.590) | 0.249 |
| N status (N2 + 3 versus N1 + 2) | 3.862 (1.443–10.339) | 0.007 | 3.157 (1.424–7.001) | 0.005 |
| Tumor size (≥5 cm versus < 5 cm) | 1.833 (0.949–3.543) | 0.071 | 1.789 (0.998–3.240) | 0.055 |

Combination of miR-939 and SLC34A2: I, High miR-939 and Low SLC34A2; II High miR-939 and High SLC34A2; III Low miR-939 and Low SLC34A2; IV Low miR-939 and High SLC34A2

Analysis was conducted using univariate or multivariate Cox proportional hazards regression

a Multivariate analysis of miR-939, SLC34A2, T status, N status and Tumor size

b Multivariate analysis of the combination of miR-939 and SLC34A2, T status, N status and Tumor size
Additional file

Additional file 1: Table S1. The clinicopathologic characteristics of the 112 GC patients who received surgery followed by adjuvant chemotherapy in this study. (DOC 40 kb)

Abbreviations
S-Fu: 5-fluorouracil; AUC: Area under the curve; CR: Complete response; FFPE: Formalin-fixed paraffin-embedded; GC: Gastric cancer; IHC: Immunohistochemical; NC: No change; OS: Overall survival; PD: Progressive disease; PR: Partial response; ROC: Receiver operating characteristic; TTR: Time to recurrence

Acknowledgements
We would like to thank Dr. Shu Xu for her valuable comments and extensive edit for the manuscript.

Funding
This work was supported by the Natural Science Foundation of China (No.81401991, No. 81225018 and No.81572359).

Authors’ contributions
SY and DX conceived and designed the experiments. JXZ and YX performed the statistical analysis. SY and DX revised the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
All data during the current study is available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The research protocol was reviewed and approved by the Ethical Committee and Institutional Review Board of the Sun Ya-Sen University. No informed consent (written or verbal) was obtained for use of retrospective tissue samples from the patients within this study, most of whom were deceased, since this was not deemed necessary by the Ethics Committee, who waived the need for consent. All samples were anonymous.

Author details
1Department of Oncology, the First Affiliated Hospital, Sun Yat-sen University, No. 58, Zhongshan road II, 510060 Guangzhou, People’s Republic of China.
2The State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, No. 651, Dongfeng Road East, 510060 Guangzhou, People’s Republic of China.
3Department of Pathology, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, No. 58, Zhongshan road II, 510080 Guangzhou, People’s Republic of China.

Received: 4 August 2016 Accepted: 9 January 2017

Published online: 27 January 2017

References
1. Lipton A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer incidence and mortality to 2030. CA Cancer J Clin. 2011;61:69–90.
2. El-Naggar A, Ajani JA. Surgical resection first for localized gastric adenocarcinoma: Are there adjuvant options? J Clin Oncol. 2013;33:3085–91.
3. Jacome AA, Coutinho AK, Lima EM, Tiffen MG,SPATH L, MA, Mejia M. Lack of microRNA-101 causes E-cadherin functional up-regulation through EZH2 up-regulation in intestinal gastric cancer. J Pathol. 2012;228:831–44.
4. Li BS, Zuo QF, Zhang HA, Zhang Y, Mao XH, Wu C, Yang SM, Zheng H, Zou QM, Guo SH, Mi R. MicroRNA-215 downregulated in gastric carcinomas and regulates the survival by targeting PDK1 and 14-3-3zeta. Cancer Res. 2014;74:2335–45.
5. Jin Z, Selaru FM, Cheng K, Yan T, Agarwal R, Wori Y, Olaru A, Yang J, David S, Hamilton JP, et al. MicroRNA-192 and –215 are upregulated in human gastric cancer in vivo and suppress AKAM expression in vitro. Oncogene. 2011;30:1577–85.
6. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.
7. Ueda T, Volinia S, Okumura H, Shimizu M, Taccidi C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 2010;11:136–46.
8. Liu Y, Zhang X, Zhang Y, Hu Z, Yang D, Wang C, Guo M, Cai Q. Identification of miRNomes in human stomach and gastric carcinomas reveals mir-133b/va-3p as a therapeutic target for gastric cancer. Cancer Lett. 2015;369:58–66.
9. Tsukamoto Y, Nakada C, Noguchi T, Taniyama M, Nguyen LT, Uchi Y, Hijima N, Matsuura K, Fujikura T, Seto M, Miyajima M. MicroRNA-223 is downregulated in gastric carcinomas and regulates the survival by targeting PDK1 and 14-3-3zeta. Cancer Res. 2014;74:2335–45.
10. Jin Z, Selaru FM, Cheng K, Yan T, Agarwal R, Wori Y, Olaru A, Yang J, David S, Hamilton JP, et al. MicroRNA-192 and –215 are upregulated in human gastric cancer in vivo and suppress AKAM expression in vitro. Oncogene. 2011;30:1577–85.
11. Carvalho J, van Grienew NC, Pozo A, von Wachter S, Tiffen MG,SPATH L, MA, Mejia M. Lack of microRNA-101 causes E-cadherin functional up-regulation through EZH2 up-regulation in intestinal gastric cancer. J Pathol. 2012;228:831–44.
12. Li BS, Zuo QF, Zhang HA, Zhang Y, Mao XH, Wu C, Yang SM, Zheng H, Zou QM, Guo SH, Mi R. MicroRNA-215 downregulated in gastric carcinomas and regulates the survival by targeting PDK1 and 14-3-3zeta. Cancer Res. 2014;74:2335–45.
13. Oh HK, Kwon SH, Lee J, Lee J, Ham SH, Shin SJ, Song HJ, Yu SH, et al. Genomic loss of miR-486 regulates tumor progression and the OLFM4 antipoptotic factor in gastric cancer. Clin Cancer Res. 2012;18:6040–51.
14. Zou QQ, Park JJ. MEK1/2 inhibitors: molecular activity and resistance mechanisms. Semin Oncol. 2015;42:894–6.
15. Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV. The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene. 2005;24:7482–92.
16. Nadu S, Magee P, Garofalo M. MRNA-based therapeutic intervention of cancer. J Hematol Oncol. 2015;8:68.
17. Xie L, Jing R, Qi J, Lin Z, Ju S. Drug resistance-related microRNAs in hematological malignancies: translating basic evidence into therapeutic strategies. Blood Rev. 2015;29:33–44.
18. Zhang JX, Qian D, Wang XB, Liao DW, Wei JH, Tong ZT, Fu J, Huang XX, Liao YJ, Deng HX, et al. MicroRNA-215 enhances the sensitivities of human nasopharyngeal carcinoma cell to cisplatin-based chemotherapy and radiotherapy. Cancer Lett. 2013;329:109–16.
19. Magee P, Shi L, Garofalo M. Role of microRNAs in chemoresistance. Ann Transl Med. 2015;3:332.
20. Dai X, Tan C. Combination of microRNA therapeutics with small-molecule anticancer drugs: mechanism of action and co-delivery nanocarriers. Adv Drug Deliv Rev. 2015;81:184–97.
21. Ying X, Li-ya Q, Feng Z, Yin W, Ji-hong L. MiR-939 promotes the proliferation of human ovarian cancer cells by repressing APC2 expression. Biomed Pharmacother. 2015;71:64–9.
22. Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. Dev Cell. 2006;11:441–50.
23. Kent OA, Mendel JT. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene. 2006;25:6188–96.
24. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433:769–73.
25. Xu H, Bai L, Collins JF, Ghishan FK. Molecular cloning, functional characterization, tissue distribution, and chromosomal localization of a human, small intestinal sodium-phosphate (Na + –Pi) transporter (SLC34A2).
26. Xu H, Bai L, Collins JF, Ghishan FK. Molecular cloning, functional characterization, tissue distribution, and chromosomal localization of a human, small intestinal sodium-phosphate (Na + –Pi) transporter (SLC34A2).
27. Zhang et al. Molecular Cancer (2017) 16:18 Page 14 of 15
28. Chen DR, Chien SY, Kuo SJ, Teng YH, Tsai HT, Kuo JH, Chung JG. SLC34A2 as a novel marker for diagnosis and targeted therapy of breast cancer. Anticancer Res. 2010;30:4135–40.

29. Zhang X, Ke X, Pu Q, Yuan Y, Yang W, Luo X, Jiang Q, Hu X, Gong Y, Tang K, et al. MicroRNA-410 acts as oncogene in NSCLC through downregulating SLC34A2 via activating Wnt/beta-catenin pathway. Oncotarget 2016;7:14569-85.

30. Wang Y, Yang W, Pu Q, Yang Y, Ye S, Ma Q, Ren J, Cao Z, Zhong G, Zhang X, et al. The effects and mechanisms of SLC34A2 in tumorigenesis and progression of human non-small cell lung cancer. J Biomed Sci. 2015;22:52.

31. Johnson GL, Stuhlmiller TJ, Angus SP, Zawistowski JS, Graves LM. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer. Clin Cancer Res. 2014;20:2516–22.

32. Deschenes-Simard X, Kottakis F, Meloche S, Ferbeyre G. ERKs in cancer: friends or foes? Cancer Res. 2014;74:412–9.

33. Pouyssegur J, Volmat V, Lenormand P. Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. Biochem Pharmacol. 2002;64:755–63.

34. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410:37–40.

35. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande Woude GF, Ahn NG. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science. 1994;265:966–70.

36. De Luca A, Maiello MR, D’Alessio A, Pergameno M, Normanno N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 2012; Suppl 2: S17–27.

37. Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, Basecke J, Stivala F, Donia M, Fagone P, Nicoletti F, et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia. 2011;25:1080–94.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit